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Inhibiting the Cannabinoid Catabolic Enzyme MAGL to Potentiate the Anti-Arthritic 
Properties of the Synthetic Glucocorticoid Dexamethasone 
Sara R. Nass 
 Rheumatoid arthritis (RA, Table 1) is the most common type of inflammatory arthritis, 
and is characterized by swelling, inflammation, pain, and destruction of the synovial joints (i.e., 
knees, elbows, wrists, hips, and fingers). Glucocorticoid receptor agonists are a type of steroid 
hormone and are among the most common treatments for inflammatory arthritis because of their 
powerful anti-inflammatory effects. However, harmful side effects are associated with these 
glucocorticoids (GCs), including increasing patients’ vulnerability to infections. Cannabinoids 
(i.e., cannabis-like signaling molecules) exert anti-inflammatory and analgesic effects with 
limited side effects compared to traditional immunosuppressants making them excellent targets 
for the development of new arthritic therapeutics. For example, in mice, selective inhibition of 
the cannabinoid enzyme monoacylglycerol lipase (MAGL) reduces acute inflammatory pain and 
edema. Dual administration of drugs are promising novel treatments because it allows lower 
doses of drugs to attenuate pain and inflammation, while limiting side effects. Combined 
administration of an endocannabinoid enzyme inhibitor and nonsteroidal anti-inflammatory drug 
reduces neuropathic and acute pain. Similarly, inflammatory arthritis is reduced by a GC 
administered with an anti-inflammatory cytokine (i.e., immune system signaling molecule) in 
mice. Given the anti-inflammatory properties of MAGL inhibition, it is plausible that MAGL 
inhibition will increase the analgesic and anti-inflammatory effects of a steroid treatment, 
perhaps reducing the negative side effects of the steroid. Therefore, the goals of the present 
studies were to determine the analgesic and anti-inflammatory efficacy of (1) the MAGL 
inhibitor JZL184; (2) the glucocorticoid steroid dexamethasone (DEX); and (3) the combined 
administration of both JZL184 and DEX. To these ends, we used the collagen-induced arthritis 
(CIA) mouse model. We found that, although both JZL184 and DEX significantly attenuated 
proinflammatory cytokine levels in the paws of CIA mice, only DEX decreased pain-related 
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Abbreviation Full Term 
2-AG 2-arachidonoylglycerol  
anandamide N-arachidonoylethanolamine  
CB1 cannabinoid receptor one 
CB2 cannabinoid receptor two 
CFA complete Freund’s adjuvant  
CIA  collagen induced arthritis 
CNS central nervous system 
DEX dexamethasone 
DMARDs disease-modifying antirheumatic drugs  
FAAH fatty acid amide hydrolase  
FLS fibroblast-like synoviocytes 
GCs glucocorticoids 






MAGL monoacylglycerol lipase  
MHC major histocompatibility complex  
MMP matrix metalloproteinase  
MPO myeloperoxidase 
RA rheumatoid arthritis 
Th1 Type 1 T helper cells  
TH17 T helper 17 cells 
THC ∆9-tetrahydrocannabinol 
TNFα tumor necrosis factor alpha 
Treg regulatory T cells 
 
Table 1. Non-standard abbreviations. 
 
 




 Rheumatoid Arthritis (RA) is a debilitating chronic joint disorder that causes mood 
disturbances and decreases activity. The most common features are swelling, inflammation, pain, 
and erosion of the synovial joints (Firestein, 2003). RA pain is primarily induced by chronic 
inflammation, and has a higher correlation with functional disability compared to joint 
destruction alone, indicating pain is a greater predictor for RA outcome (Sokka, Kankainen, & 
Hannonen, 2000). Chronic inflammation and tissue damage in RA is causes by a failure of the 
host's immune system to discriminate between self and non-self tissue, thus RA is an 
autoimmune disorder (Lindstrom & Robinson, 2010). The following sections cover a primer on 
the immune system and the inflammatory response as it relates to RA, followed by background 
on the endocannabinoid system, and rationale for combined targeting of both immune and 
cannabinoid systems to combat inflammatory arthritis in the proposed mouse model. 
The Immune System 
Although the immune system protects the host from pathogens (e.g., viruses and 
bacteria), an inflammatory response can also be initiated against self-tissue (i.e., autoimmunity) 
or non-threatening environmental stimuli (e.g., allergy). The two main branches of the immune 
system are innate and adaptive immunity. Innate immunity is non-specific and mounts a swift 
immune response in a consistent manner, even after multiple presentations of the same pathogen 
(Abbas, Litchman, & Pober, 2002). In contrast, a specific response to the presence of pathogens 
is developed by adaptive (i.e., acquired) immunity. A distinct response and memory for 
individual pathogens is acquired, so a quicker and more intense response can be mounted after 
repeat exposure. Adaptive immunity is essential in vaccinations, but also autoimmune disorders 
such as RA. After immunization with a weakened or killed pathogen, adaptive immunity 
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develops memory, causing a more powerful immune response when the pathogen is encountered 
in the future (Abbas et al., 2002). The adaptive immune system is normally nonreactive to tissues 
originating from the host. However, this tolerance to self-tissue can break down and lead to 
autoimmunity (Lindstrom & Robinson, 2010).  
 Although there are many different cells involved in the inflammatory response, only the 
cells most relevant to the proposed project will be discussed here (see Figure 1). The short-lived 
innate leukocytes (i.e., white blood cells), neutrophils, are the first cells to be activated during the 
inflammatory response and attract macrophages and dendritic cells to the site of inflammation 
(Nathan, 2006). Neutrophils express a substantial amount of the enzyme myeloperoxidase 
(MPO), which can be analyzed as an indirect measure of neutrophil activity (Al-Abd et al., 
2014). Monocytes are immature innate leukocytes that circulate in the blood and differentiate 
into macrophages when recruited to inflamed tissue (Abbas et al., 2002). Macrophages release 
pro-inflammatory cytokines (i.e., the “hormones” of the immune system), and engage in 
phagocytosis (i.e., engulfing harmful molecules) and antigen presentation (Boissier, Semerano, 
Challal, Saidenberg-Kermanac'h, & Falgarone, 2012). Dendritic cells bridge the gap between 
innate and adaptive immunity by engulfing antigens (i.e., substances that induce antibody 
production) and presenting them via major histocompatibility complex (MHC) class II 
molecules to T cells of the adaptive immune system. Activated helper CD4+T cells then migrate 
from lymph nodes to the site of inflammation. The Type 1 T helper (Th1) and T helper 17 
(Th17) cell subtypes are considered proinflammatory and activate leukocytes; whereas 
regulatory T cells (Tregs) release anti-inflammatory cytokines (Rabb, 2002). B cells of the 
adaptive immune system release antibodies that bind to antigens (Rabb, 2002).  
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 Cytokines are signaling molecules that modulate the immune response. Cytokines are 
pleiotropic (i.e., activate a variety of leukocytes) and redundant (i.e., different cytokines have 
similar effects). Proinflammatory cytokines stimulate leukocyte activation, to eliminate antigens 
and synthesize more cytokines. The pro-inflammatory cytokines tumor necrosis factor alpha 
(TNFα) and interleukin-1beta (IL-1β) are mainly produced by macrophages and stimulate 
leukocytes; whereas interleukin-17A (IL-17A) is produced by Th17 cells and induces 
proinflammatory cytokine production (Boissier et al., 2012; Shahrara, Huang, Mandelin, & Pope, 
2008). The proinflammatory cytokine interleukin-6 (IL-6) is released from a variety of 
 
Figure 1. Schematic drawing of the immune response in RA. During RA pathogenesis immune 
cells migrate to the joint synovium. Neutrophils are the first cells recruited to the site of 
inflammation. Macrophages proliferate in the synovium to ingest foreign bodies and produce 
proinflammatory cytokines (e.g., IL-1β, TNFα, & IL-6). Cytokines are signaling molecules that 
mediate inflammation. Dendritic cells present self-antigens to T cells that migrate from the 
lymph nodes into the synovium. T cells activate leukocytes and also produce proinflammatory 
cytokines (e.g., IL-17). The anti-inflammatory cytokine IL-10 is also produced by T cells, but 
there is an imbalance in favor of pro-inflammatory cytokines. B cells produce autoantibodies 
against self-tissue. The immune cells in the synovium form a pannus (i.e., abnormal layer of 
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leukocytes and induces antibody production (Boissier et al., 2012). Some cytokines have 
predominantly anti-inflammatory effects. For example, the anti-inflammatory cytokine 
interleukin-1 (IL-10) is produced by Treg cells and reduces inflammation and regulates the 
inflammatory response, helping return the host to homeostasis after pathogen elimination (Chen 
et al., 2012).  
Inflammatory Response in Rheumatoid Arthritis  
 Although the exact etiology of RA is not well understood, the progression of 
inflammation involves the innate and adaptive immune systems (see Figure 1). The synovium 
(i.e., the soft tissue lining of synovial joints, such as knuckles) is the main site of inflammation 
and tissue destruction in RA (Smith, 2011). Genetic susceptibility to RA is associated with 
specific variations of the genes that encode for MHC class II molecules expressed on antigen 
presenting cells (e.g., dendritic cells and macrophages) (Roudier, 2006). There is an increase in 
activated macrophages within the RA synovium that release pro-inflammatory cytokines (e.g., 
TNFα, IL-1β, and IL-6) (McInnes & Schett, 2011). During RA pathogenesis, self-tissues are 
presented by MHC class II molecules on dendritic cells and macrophages to helper T cells. 
Within the synovium and blood of RA patients, proinflammatory Th1 and Th17 helper T cell 
subtypes increase in number, while anti-inflammatory Treg helper T cells decrease (Chen et al., 
2012; Shahrara et al., 2008). Immune memory develops when proinflammatory cytokines 
stimulate cells to produce autoantibodies (e.g., rheumatoid factor) against self-tissue, resulting in 
further inflammation in the synovium (Takemura, Klimiuk, Braun, Goronzy, & Weyand, 2001). 
Thus, the initial innate immune response to self-tissue becomes an acquired immune response to 
self-tissue that generally targets tissues in the synovial joints. 
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 Within the RA synovium there is an abundance of the proinflammatory cytokines TNFα, 
IL-1β, IL-6, and IL-17 (McInnes & Schett, 2007; Shahrara et al., 2008). These cytokines are also 
expressed in the serum of RA patients, but not healthy volunteers, indicating an upregulation of 
proinflammatory cytokines throughout the body (Chen et al., 2012). The presence of IL-10 in 
RA serum and joints indicates a failure of the immune system to keep RA inflammation in check 
(Chen et al., 2012). Proinflammatory cytokines induce inflammatory pain by decreasing 
nociceptor (i.e., free nerve ending that acts as a receptor for pain) activation threshold (Kidd & 
Urban, 2001). 
 In addition to leukocytes, fibroblast-like synoviocytes (FLS) are mesenchymal cells that 
proliferate and adhere to the cartilage in RA joints. FLS activated by TNFα and IL-1β 
aggressively destroy RA joints by releasing more proinflammatory cytokines and matrix 
metalloproteinase (MMPs) that degrade the cartilage extracellular matrix (Karouzakis, Neidhart, 
Gay, & Gay, 2006). Chronic inflammation and the release of cartilage degrading MMPs causes 
the synovium to become hyperplastic and develop pannus (i.e., an abnormal tissue layer), 
eventually leading to cartilage destruction and bone erosion (Karouzakis et al., 2006; McInnes & 
Schett, 2011).  
Current Rheumatoid Arthritis Treatments 
 Reducing RA symptoms typically involves decreasing joint inflammation and the 
resulting pain perception. Immunosuppressants, including disease-modifying antirheumatic 
drugs (DMARDs), glucocorticoids (GCs), and biologic therapies are the most common 
pharmacological treatments used to slow RA progression (Singh et al., 2016). However, 
immunosuppressants can induce aversive side effects, and patients often experience pain despite 
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improvement in inflammation (Lee, 2013). For example, DMARDs, such as methotrexate reduce 
pain in addition to inflammation, but need to be administered early to exert analgesic effects. 
Efficacy of DMARDs as analgesics decreases when introduced even just twelve months after 
diagnosis (Nell et al., 2004). Biologic therapies suppress specific components of the immune 
system. However, they are associated with higher annual healthcare expenditure compared to 
other immunosuppressants, and in some patients are ineffective at slowing the progression of 
joint damage or reducing symptoms (Walsh & McWilliams, 2012). 
 Steroids are clinically useful at quickly reducing inflammation and associated pain, but 
can induce harmful metabolic side effects (Singh et al., 2016). GCs are steroid hormones that are 
produced from cholesterol in the cortex of the adrenal glands. GCs bind to cytosolic GC 
receptors within cells to regulate gene expression. Steroids decrease immune cell recruitment 
through inhibition of the transcription of genes that encode proinflammatory cytokines (Coutinho 
& Chapman, 2011). In peripheral blood mononuclear cells taken from RA patients, GCs inhibit 
the production of the proinflammatory cytokines TNFα, IL-1β, IL-6, and IL-17 (Colin et al., 
2010; Schlaghecke, Beuscher, Kornely, & Specker, 1994). Due to their potent anti-inflammatory 
effects, synthetic GCs such as prednisone are effective at treating RA and other inflammatory 
diseases. However, GCs also activate expression of genes involved in metabolic processes 
(Coutinho & Chapman, 2011). Therefore, long term use increases the risk of serious aversive 
effects, including adrenal insufficiency, osteoporosis, diabetes, and cardiovascular risk 
(Ravindran, Rachapalli, & Choy, 2009). Due to the aforementioned side effects, GCs are mainly 
administered at low doses for maintenance therapy, or at high doses for short term use to reduce 
inflammation during “flare-ups” (J. F. Ferreira, Ahmed Mohamed, & Emery, 2016). Although 
immunosuppressive treatments are effective at slowing disease progression they can lead to 
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serious side effects because they dampen the immune response. The main obstacle in 
immunosuppressant use is the increased susceptibility to infections, such as tuberculosis and 
hepatitis (Furst, 2010). 
Inflammatory Arthritis Model 
 Preclinical animal models of inflammatory arthritis are used to study RA mechanisms 
and treatments. The collagen-induced arthritis (CIA) model of inflammatory arthritis is the most 
extensively used animal model to research the pathogenesis of RA progression and potential 
novel treatments (Brand, Latham, & Rosloniec, 2007; Williams, Feldmann, & Maini, 1992). CIA 
is induced by immunizing mice with a mixture of type II collagen and complete Freund’s 
adjuvant (CFA) (Brand et al., 2007; Kinsey, Naidu, Cravatt, Dudley, & Lichtman, 2011b). Mice 
will develop anti-collagen antibodies and three to seven weeks after the initial immunization 
swelling and redness develop in one or more paws (Brand et al., 2007). Although the 
development of CIA is accelerated compared to RA, the pathogenesis of both is perpetuated by 
synovial infiltration of neutrophils as measured by the enzyme myeloperoxidase (MPO) (Al-Abd 
et al., 2014), autoreactive lymphocytes (i.e., T cells and B cells) (Seki et al., 1988; Svensson, 
Jirholt, Holmdahl, & Jansson, 1998), activation of macrophages and FLS (Holmdahl, Tarkowski, 
& Jonsson, 1991; Nishioku et al., 2012), and increased proinflammatory cytokine production 
(e.g., TNFα, IL-1β, and IL-6) (Rioja, Bush, Buckton, Dickson, & Life, 2004). Similar to RA, the 
inflammatory response and synovial pannus in CIA eventually leads to cartilage destruction and 
joint damage (Asquith, Miller, McInnes, & Liew, 2009; Brand et al., 2007). Thus, CIA and 
human inflammatory arthritis are mechanistically linked. 
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The Endocannabinoid System 
 Cannabinoid agonists, such as ∆
9
-tetrahydrocannbinol (THC), the main psychoactive 
component of Cannabis, bind to and activate the G-protein-coupled receptors, cannabinoid 
receptor 1 (CB1) and cannabinoid receptor 2 (CB2) (Mechoulam & Parker, 2013). CB1 mediates 
the central nervous system (CNS) effects of cannabinoids (e.g., pain, hypothermia, and cognitive 
and behavioral deficits) and is expressed throughout the body, including in the synovium of RA 
patients and on FLS (Crowe, Nass, Gabella, & Kinsey, 2014; Gui et al., 2014; Richardson et al., 
2008). On the other hand, CB2 is expressed mainly on immune cells, but is also expressed at low 
levels in the CNS, including on activated microglia (i.e., the macrophages of the CNS) (Cabral, 
Raborn, Griffin, Dennis, & Marciano-Cabral, 2008). In the RA synovium, CB2 is expressed on 
macrophages, T cells, and B cells, as well as FLS (Fukuda et al., 2014; Gui et al., 2014; Selvi et 
al., 2008). The presence of cannabinoid receptors in RA joints presents a possible target for 
novel anti-inflammatory and analgesic treatments. 
 One of the main mechanisms of cannabinoid modulation of inflammation is the 
regulation of cytokines. For example, THC attenuates the release of the pro-inflammatory 
cytokines IL-6 and TNFα in vitro from macrophages stimulated by the bacterial endotoxin 
lipopolysaccharide (Chang, Lee, & Lin, 2001; Fischer-Stenger, Updegrove, & Cabral, 1992). 
FLS cultured from RA synovial tissue and stimulated with the pro-inflammatory cytokines TNFα 
or IL-1β, produce and release the pro-inflammatory cytokine IL-6. Pan cannabinoid agonists, 
such as WIN-55,212-2 and CP55940 (Lowin, Pongratz, & Straub, 2016; Selvi et al., 2008), as 
well as the selective CB2 agonists, HU-308 and JWH133 (Fukuda et al., 2014; Gui et al., 2014), 
attenuate the secretion of IL-6 from stimulated FLS. Similarly, the endogenous cannabinoid, 
anandamide also attenuates TNFα stimulated FLS production of IL-6 and IL-8 (Lowin, Apitz, 
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Anders, & Straub, 2015). These data suggest that cannabinoids may reduce RA inflammation by 
attenuating the release of pro-inflammatory cytokines from FLS in the synovium. 
Many exogenous cannabinoid agonists have undesirable behavioral and cognitive effects, 
including deficits in attention, memory, and motor function. Furthermore, chronic administration 
can lead to tolerance and abuse (Mechoulam & Parker, 2013). One way to bypass the abuse 
potential and psychomimetic side effects of cannabinoid agonists is to target the endogenous 
cannabinoid (i.e., endocannabinoid) system. The two major endocannabinoids, N-
arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), are synthesized 
de novo from phospholipid precursors, and bind to and activate both cannabinoid receptors 
(Mechoulam & Parker, 2013). Within the CNS, 2-AG is more abundant than anandamide, and 
acts as a full agonist at the CB1 and CB2 receptors (Ahn, McKinney, & Cravatt, 2008). 2-AG is 
also present in the synovium of RA patients and throughout other areas of the body, including 
the spleen (i.e., lymphoid organ important in the immune system) (Hillard, 2000; Richardson et 
al., 2008). Monoacylglycerol lipase (MAGL) is the predominant catabolic enzyme for 2-AG, 
and metabolizes 2-AG into glycerol and arachidonic acid (Blankman, Simon, & Cravatt, 2007). 
Pharmacological inhibition of MAGL, for example by the highly selective MAGL inhibitor 
JZL184, increases 2-AG systemically (Long et al., 2009). JZL184 attenuates acute inflammatory 
pain and edema induced by injecting the seaweed extract carrageenan (Ghosh et al., 2012). 
However, there are no published reports on the effects of MAGL inhibition in chronic 
inflammatory pain models, such as arthritis. 
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Cannabinoids in Inflammatory Arthritis 
 Although cannabinoids are anti-inflammatory and analgesic with limited side effects 
compared to traditional immunosuppressants, research focused on the effects of cannabinoids in 
chronic inflammatory arthritis in vivo is limited. The oromucosal mouth spray Sativex, which 
contains a mixture of the Cannabis extracts THC and cannabidiol, decreases self-reports of RA-
induced pain in humans (Blake, Robson, Ho, Jubb, & McCabe, 2006). In the preclinical CIA 
model, repeated administration of cannabidiol, or its synthetic cannabinoid derivatives, decreases 
paw swelling and cartilage destruction (Haj et al., 2015; Malfait et al., 2000; Sumariwalla et al., 
2004). Cannabidiol also attenuates the production of TNF-α from CIA synovial cells (Malfait et 
al., 2000). Similarly, CIA-induced inflammation, cartilage degradation, and bone erosion is also 
attenuated by the repeated administration of the selective CB2 agonists JWH133 and HU-308 
(Fukuda et al., 2014; Gui, Liu, Liu, Su, & Dai, 2015).  
In addition to synthetic cannabinoid agonists, there is evidence that the endocannabinoid 
system modulates CIA. Just as MAGL catabolizes 2-AG, fatty acid amide hydrolase (FAAH) 
catabolizes the other endocannabinoid, anandamide. FAAH inhibition or genetic deletion 
increases tissue levels of anandamide. Genetic deletion of FAAH or repeated administration of 
the FAAH inhibitors URB597 or JNJ1661010 attenuates clinical signs of arthritis, and genetic 
deletion of FAAH attenuates joint damage in mice subjected to CIA (Kinsey et al., 2011b; Lowin 
et al., 2015). Interestingly, the FAAH inhibitor URB597 or genetic deletion of FAAH also 
reduces CIA-induced thermal hyperalgesia (i.e., hypersensitivity to noxious heat) (Kinsey et al., 
2011b). These data from human and animal studies suggest that endocannabinoids attenuate 
inflammatory joint pain and overt signs of joint inflammation. 
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Combination Treatments  
 In contrast to the classic approach of targeting a disease with a single drug, combined 
administration of multiple drugs offers several advantages. Combination therapies may maintain 
analgesic and anti-inflammatory efficacy by using lower doses of each drug, thereby decreasing 
the negative side effects (van Laar et al., 2012). In addition, chronic pain is often induced by 
multiple mechanisms. Although inflammation is the main perpetrator of RA pain, many patients 
also develop central sensitization, an increase in CNS pain pathway activity that causes 
hypersensitivity (Lee, 2013). Therefore, addressing multiple targets may increase the efficacy of 
the drug regimen. 
 The synthetic glucocorticoid receptor agonist dexamethasone (DEX) is used in 
preclinical research and reduces inflammation in the CIA model (Inglis et al., 2007a). A 
combination of DEX and the anti-inflammatory cytokine IL-4 attenuates CIA-induced paw 
inflammation (Kang et al., 2000; Kawalkowska et al., 2016). Interestingly, the combination of 
DEX and IL-4 also prevents the resurgence of CIA-induced paw swelling after treatment is 
terminated, indicating combination therapies may limit the need for long term use of 
glucocorticoids (GCs), thereby reducing undesirable side effects (Kawalkowska et al., 2016). 
Thus, there is evidence to support the idea that combining therapeutics with GCs may also 
reduce pain and inflammation in models of inflammatory arthritis with increased efficacy and 
decreased side effects. Endocannabinoid catabolic enzyme inhibition attenuates hyperalgesia and 
clinical signs of arthritis in the CIA model (Kinsey et al., 2011b), and the synthetic 
glucocorticoid receptor agonist DEX attenuates CIA-induced inflammation (Inglis et al., 2007a). 
The present study was designed to determine the analgesic and anti-inflammatory efficacy of (1) 
the MAGL inhibitor JZL184; (2) the glucocorticoid steroid dexamethasone (DEX); and (3) the 
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combined administration of both JZL184 and DEX. Our overall goal was to ascertain whether 
pain and inflammation caused by inflammatory arthritis are further reduced by targeting both 
glucocorticoid and cannabinoid receptors than by targeting either receptor system alone. 
Methods 
Animals 
Subjects were 226 male DBA/1J (Jackson Laboratory, Bar Harbor, ME) mice 9-12 weeks 
old at the start of the experiment. Males were chosen because multiple reports (Holmdahl, 
Jansson, & Andersson, 1986; Jansson & Holmdahl, 2001; Nilsson, Andren, Diaz de Stahl, & 
Kleinau, 2009) indicate that female mice are protected from collagen induced arthritis and rarely 
develop arthritis. Mice were housed 3-5 per cage in a temperature (20-22°C) and humidity 
controlled, AAALAC accredited facility, with ad libitum access to food and water, on a 12:12 
light:dark cycle. The Institutional Animal Care and Use Committee at West Virginia University 
approved all the experimental protocols (14-1007). 
Collagen Induced Arthritis (CIA) Inflammatory Arthritis 
 A timeline of the treatments is illustrated in Figure 2. Mice were anesthetized with 
isoflurane (Phoenix Pharmaceuticals, Burlingame, CA), and approximately 100 µl of an 
emulsion of bovine type II collagen (2 mg/ml), dissolved in 0.05 M acetic acid, in an equal 
volume of CFA was injected intradermally into the tail. Twenty-one days later (Brand et al., 
2007; Impellizzeri et al., 2013), mice were given a secondary "booster" exposure to the collagen 
preparation, in an equal volume of incomplete Freund’s adjuvant (IFA), slightly proximal from 
the first injection (Brand et al., 2007). Control mice were administered an emulsion of IFA and 
acetic acid, without collagen, at both exposures (Brand et al., 2007). The difference between 
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CFA and IFA is that CFA contains heat-inactivated bacteria, to cause an innate immune response 
at the injection site. The CFA in the proposed experiment consisted of M. tuberculosis (4 mg/ml) 
(Becton, Dickinson and Company, Franklin Lakes, NJ) suspended into 85% paraffin oil (Fisher 
Scientific, Pittsburgh, PA) and 15% mannide monooleate (Fisher Scientific, Pittsburgh, PA) 
(Brand et al., 2007).   
 At the conclusion of the experiments, mice were humanely euthanized and hind limb 
tissue were collected, snap frozen in liquid nitrogen, and stored at -80°C until assay.  
Paw edema and clinical scoring 
After the “booster” injection, all four paws were examined daily for arthritic signs using a 
semi-quantitative clinical scoring system as follows: 0, normal; 1, erythema and mild swelling 
 
Figure 2. Timeline of collagen-induced arthritis (CIA) progression. Mice were 
immunized with collagen/CFA and given a “booster” exposure to the collagen 21 days 
later. Starting at the booster, mice were administered drug for 15-20 days and assessed 
daily for paw swelling. Mice were tested behaviorally on day 15 or 19 of repeat 
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confined to the ankle joint or toes; 2, erythema and mild swelling extending from the ankle to the 
midfoot or ankle joint; 3, erythema and moderate swelling extending from the ankle to the 
metacarpal/metatarsal joints; 4, erythema and severe swelling encompassing the ankle, foot, and 
digits (Kinsey et al., 2011b). The scores for each limb were summed for each mouse, resulting in 
a composite arthritis score with a maximum of 16 total points. Hind paw thickness was also 
measured with a digital micrometer, daily until the end of the experiment (Wixey WR100). Data 
from our lab as well as others indicate that CIA does not develop in our model until the “booster” 
collagen administration and daily handling before the booster reduces arthritis incidence (Brand 
et al., 2007). 
Behavioral Assessments 
 Behavioral assessments of mechanical allodynia (i.e., pain perception to non-noxious 
touch) and thermal hyperalgesia were conducted on mice subjected to the CIA model of 
inflammatory arthritis. Mice were randomly assigned to each drug treatment at the start of each 
experiment and repeatedly dosed for 15-20 days (see Table 2). Repeated dosing and behavioral 
testing schedules were based on the established timeline for mice to develop signs of arthritis and 
preliminary data (see Figure 2 and results) (Brand et al., 2007; Gao et al., 2015). Given that the 
effects of MAGL inhibition on chronic inflammation are unknown, we used a prophylactic 
design, with the goal of increasing the likelihood of detecting an effect of the novel drug 
treatments. On behavioral testing days, mice were tested for allodynia followed by hyperalgesia. 
The experimenter was blinded to treatments throughout testing. Independent experimenter 
reliabilities for behavioral tests and caliper measurements were performed at multiple time points 
throughout the experiment and were correlated to > 0.98.  
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 Mechanical allodynia. On test days, mice were brought into the testing room, weighed 
and injected. Immediately afterwards, mice were placed in ventilated polycarbonate chambers 
(7.5 x 9 cm) on an aluminum mesh table where they were allowed to acclimate for at least 60 
min before testing mechanical allodynia (Kinsey et al., 2009). Mechanical allodynia was tested 
by stimulating the plantar surface of each mouse hind paw with von Frey filaments (North Coast 
Medical, Morgan Hill, CA) using the  “up-down” method (Chaplan, Bach, Pogrel, Chung, & 
Yaksh, 1994; Crowe et al., 2015). Von Frey filaments are commonly used to test touch 
sensitivity in humans and other animals and are calibrated to bend at established weights. Each 
hind paw is stimulated approximately twice per second with each filament (0.16-6.0 g), starting 
with the 0.6 g filament. Hind paws were stimulated in ascending filament order until the mouse 
clutched or lifted its paw at least three out of five times. This was considered a positive response, 
and the sensitivity of each paw was tested by presenting the filaments in descending order to 
establish a sensory threshold. 
Thermal Hyperalgesia. Mice were placed in ventilated polycarbonate chambers (7.5 x 9 
cm) on a glass table and acclimated for at least 60 min before testing thermal hyperalgesia 
(Lichtman, Shelton, Advani, & Cravatt, 2004). Thermal hyperalgesia was tested using the plantar 
stimulator apparatus (Hargreaves, Dubner, Brown, Flores, & Joris, 1988; Lichtman et al., 2004). 
A plantar stimulator with a noxious heat source was positioned directly beneath the hind paws of 
each mouse, under a glass table. The latency for the mouse to withdraw its hind paw from the 
initiation of the radiant heat was scored as the dependent variable. A 20 s cutoff time was used to 
avoid the possibility of tissue damage (Kinsey et al., 2011a; Lichtman et al., 2004).  
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Cytokine and Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA) 
 Paw cytokine and MPO protein levels were quantified by sandwich ELISA, per 
manufacturer’s protocol (R&D Systems, Minneapolis, MN). Paw samples were separated at the 
ankle joint, cut into small pieces, and homogenized in 1.5 ml phosphate-buffered saline using a 
Tissue Tearor (Bartlesville, OK). Proinflammatory (TNFα, IL-1β, IL-6, IL-17) and anti-
inflammatory (IL-10) cytokines, and MPO were quantified in duplicate. 
In brief, 96 well plates were coated with an anti-mouse capture antibody (derived from 
goat or rat immune cells that were exposed to the target mouse protein) and incubated at room 
temperature overnight. The following day, the samples and standards were added to each plate 
and incubated at room temperature for 2 h. Samples were decanted and each plate was washed 3 
times with wash buffer (0.05% Tween 20 in phosphate buffered saline). A detection antibody 
was then added to each well and incubated at room temperature for 2 h. The protein of interest 
(i.e., cytokine or MPO) became “sandwiched” between the capture antibody and detection 
antibody. Horseradish peroxidase (Streptavidin-HRP) was then added to each well and incubated 
for 20 min. HPR linked the detection antibody to a chemical tag (i.e., a 1:1 mixture of H2O2 and 
Tetramethylbenzidine) that produced color. The color reaction was halted after 20 min 
incubation in the dark by 2 N H2SO4. Optical densities were determined with a V max kinetic 
microplate reader (Molecular Devices, Sunnyvale, CA) and read at 450 nm with a 560 nm 
correction. Values for known standards on each plate were plotted. The optical density of each 
unknown sample was fitted to this standard curve to determine the concentration of cytokine or 
MPO in each sample. Data are reported as the mean of the duplicates. No values were excluded 
for being above detection limit. The detection limit (protein (min/max)) in pg/ml for each assay 
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were as follows: TNFα (2000/31.3), IL-1β (1000/15.6), IL-6 (1000/15.6), IL-17 (1000/15.6), IL-
10 (2000/31.3), and MPO (16000/250). 
Drugs  
 The MAGL inhibitor JZL184 was purchased from Cayman Chemical (Ann Arbor, MI). 
The synthetic glucocorticoid DEX was purchased from Sigma-Aldrich (St Louis, MO). Both 
drugs were dissolved in a vehicle consisting of ethanol, Cremophor (Sigma-Aldrich, St Louis, 
MO), and saline in a ratio of 1:1:18 parts (Crowe et al., 2015; Kinsey & Cole, 2013). All 
solutions were administered at room temperature at a volume of 10 µl/g body weight.  
Statistical Analyses  
Induction of CIA effect (as compared to non-CIA controls), was determined using 
unpaired t-tests with mechanical allodynia, thermal hyperalgesia, cytokine level, or MPO level as 
the dependent variable. All other data were analyzed using analysis of variance (ANOVA), 
followed by Tukey post hoc comparisons, with the exception of the DEX dose response data, for 
which Dunnett's post hoc comparison was used instead (all doses compared with CIA/VEH). For 
the first experiment, JZL184 data and DEX dose response data were analyzed using one way 
between subjects ANOVA with treatment (CIA/VEH, CIA/JZL184, CIA/DEX) as the 
independent variable and mechanical allodynia, thermal hyperalgesia, cytokine level, or MPO 
level as the dependent variable. In the second experiment, a one-way between subjects ANOVA 
of treatment condition (CIA/VEH, CIA/JZL184, CIA/DEX, CIA/JZL184+DEX) as the 
independent variable and mechanical allodynia, thermal hyperalgesia, cytokine level, or MPO 
level as the dependent variable was conducted, followed by Tukey post hoc comparisons. Data 
for clinical scores and edema were compared using mixed design ANOVA with days post 
immunization as the within subject variables and treatment as the between subjects variables. All 
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An outline of the experimental design is summarized in Figure 3. Preliminary 
experiments were performed to determine the optimal behavioral testing days for mice subjected 
to CIA. Mice were administered a collagen/CFA emulsion to induce CIA, followed 21 days later 
by a booster exposure to collagen. Separate non-CIA control mice were also tested. Paw edema 
was assessed daily using digital calipers and arthritis severity was scored using a semi-
quantitative clinical scale. Mice were tested for mechanical allodynia and thermal hyperalgesia 
 
Figure 3. Diagram of experimental design. In the first experiment mice were 
subjected to CIA and the anti-arthritic efficacy of the MAGL inhibitor 
JZL184 and the glucocorticoid DEX was established. In the second 
experiment the analgesic and anti-inflammatory effects of the combination of 
JZL184 and DEX in the CIA model was elucidated. Mice were assessed for 
paw swelling, allodynia, and hyperalgesia. Then hind paws were dissected to 
analyze cytokine (TNFα, IL-1β, IL-6, IL-17, and IL-10) and MPO levels. 
Exp 1a: JZL184
Paw edema, clinical scoring, 
pain behavior,  ELISAS
Exp 1b: DEX
Paw edema, clinical scoring, 
pain behavior, ELISAS
Exp 2: JZL184 + DEX combination
Exp 2a: 
Paw edema, clinical 
scoring, pain behavior
Exp 2b: 
Cytokine & MPO ELISAs
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(Impellizzeri et al., 2013; Kinsey et al., 2009; Kinsey et al., 2011b) on days 22, 25, 28, 31, and 
34 post immunization to determine the optimal behavioral testing timeline. Planned comparisons 
were used to establish appropriate testing days for the proceeding experiments, as choosing the 
optimal test day was the rationale for running these experiments.   
The goal of the first experiment was to determine the appropriate doses of the MAGL 
inhibitor JZL184 (Exp1a) or the steroid DEX (Exp1b) to combine in the CIA model of 
inflammatory arthritis.  
Exp1a. Determine anti-arthritic efficacy of the selective MAGL inhibitor JZL184. Mice 
were subjected to CIA or control procedures. Starting at the booster individual mice were 
administered a dose of JZL184 (8 mg/kg) (Kinsey et al., 2013; Schlosburg et al., 2010) or 
vehicle once daily, for 15 consecutive days (i.e., days 21-35; see Table 2). Separate non-
CIA control mice were also tested. Paw edema was assessed daily using digital calipers 
and arthritis severity was scored using a semi-quantitative clinical scale. Mice were tested 
for mechanical allodynia and thermal hyperalgesia (Impellizzeri et al., 2013; Kinsey et 
al., 2009; Kinsey et al., 2011a) on day 14 of repeated dosing. On the 15
th
 day of repeated 
dosing, mice were humanly euthanized and hind limb tissues were collected. It was 
hypothesized that JZL184 (8 mg/kg) would attenuate CIA-induced paw swelling and 
behavioral pain responses.  
 A separate group of mice were subjected to CIA and administered a dose of 
JZL184 (4 mg/kg) (Kinsey et al., 2013; Schlosburg et al., 2010) or vehicle once daily, for 
15 consecutive days. Disease progression was assessed via paw swelling, clinical scoring, 
allodynia, and hyperalgesia (see Table 2). On the 15
th
 day of repeated dosing, mice were 
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humanly euthanized and hind limb tissues were collected. Due to a lack of allodynic or 
hyperalgesic effect of CIA, mice were dosed consecutively for an additional three days 
and tested for grip strength (see Appendix A) on day 16 and humanly euthanized and 
hind limb tissue were collected on day 18. It was hypothesized that JZL184 (4 mg/kg) 
would be subeffective at attenuating CIA-induced paw swelling and behavioral pain 
responses. 
Exp1b. Determine anti-arthritic efficacy of the synthetic glucocorticoid steroid 
dexamethasone. As in Exp1a, CIA was induced and a dose response curve was 
constructed to establish the anti-inflammatory and analgesic potency of the synthetic 
steroid dexamethasone (DEX; 0.0625, 0.125, 0.25, or 0.5 mg/kg) (Inglis et al., 2007a). 
For 15 consecutive days, mice were administered a dose of DEX or vehicle and then 
assessed for paw swelling, disease progression (i.e., clinical scoring), allodynia, and 
hyperalgesia (see Table 2). Due to the powerful anti-inflammatory effects of DEX, a 
second cohort of mice was run to test even lower doses of dexamethasone (i.e., 0.015625, 
0.03125, or 0.5 mg/kg) than originally proposed. For 15 consecutive days, mice were 
administered a dose of DEX or vehicle and then assessed for paw swelling, disease 
progression, allodynia, and hyperalgesia (see Table 2). Due to a lack of a behavioral 
effect of CIA, mice were dosed consecutively for an additional five days and retested on 
day 19, and humanly euthanized, and hind limb tissue were collected on day 21. It was 
hypothesized that DEX would dose dependently attenuate CIA-induced paw swelling and 
pain responses.  
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 The goal of the second experiment was to determine the analgesic and anti-inflammatory 
effects of repeated combined administration of both the MAGL inhibitor JZL184 and the 
synthetic glucocorticoid DEX in the CIA model of inflammatory arthritis.  
Exp2a. Determine the behavioral and arthritic effects of dual administration of 
subeffective doses of both JZL184 and dexamethasone. Mice were administered JZL184 
(4 mg/kg), DEX (0.015625 mg/kg), JZL184 (4 mg/kg) +DEX (0.015625 mg/kg), or 
vehicle once daily, for 15 consecutive days following the booster exposure to collagen 
(i.e., day 21) (see Table 2). During repeated drug administration, mice were assessed 
daily for gross signs of paw inflammation and disease progression was assessed by 
clinical scoring. After 15 days of treatment (i.e., day 35), each mouse was tested for 
allodynia, and hyperalgesia, as detailed above. Again, due to a null CIA effect in the 
behavioral tests, mice were consecutively dosed for another four days and retested on day 
19, humanly euthanized, and hind limb tissues were collected. It was hypothesized that 
the combination of subeffective doses of JZL184 and DEX would attenuate CIA-induced 
paw swelling and pain responses to a greater degree than either drug alone. 
Cannabinoid and Steroid Interaction in Arthritis  23 
 
 
Exp2b. Determine the inflammatory effects of dual JZL184/DEX administration. Hind 
paws were dissected and homogenized to analyze proinflammatory (TNFα, IL-1β, IL-6, 
and IL-17) and anti-inflammatory (IL-10) cytokine and myeloperoxidase (MPO) levels 
using sandwich ELISA. It was hypothesized that the combination of JZL184 and DEX 




Table 2. Treatment groups and total sample size for each experiment. 




Mice 12 12 12
Experiment 1a: JZL184 Dosing
Condition Control CIA CIA CIA CIA CIA
DEX 
(mg/kg)
0 0 0.0625 0.125 0.25 0.5
Mice 10 10 9 10 9 10
Experiment 1b: DEX DRC
Control CIA
VEH VEH JZL184
Vehicle 9 11 8
DEX - 9 9
Experiment 2: Combination JZL + DEX




Mice 10 10 10
Condition Control CIA CIA CIA CIA
DEX 
(mg/kg)
0 0 0.015625 0.03125 0.5
Mice 10 10 9 9 9




Preliminary data: CIA induces paw swelling and thermal hyperalgesia 
 Due to the inconsistencies with the CIA model in our lab in the past, we first ran a pilot 
group of mice to demonstrate that we could induce CIA and to establish a behavioral timeline. 
Mice were immunized with collagen to induce CIA, and given a booster exposure to collagen 21 
days later. A group of non-CIA control mice were given control emulsions. CIA induced an 
increase in arthritic clinical scores [F(1, 15) = 21.547; p <.01; Figure 4A] and paw thickness [F 
(1, 15) = 7.693; p <.01; Figure 4B] compared to non-CIA controls. 
Mice were tested for mechanical allodynia and thermal hyperalgesia on days 22, 25, 28, 
31, and 34 post immunization. In the von Frey test, there was no interaction between treatment 
and days post immunization [F(4, 22) = .6786, p = .1347; Figure 4C], nor was there a main 
effect of treatment [F(1, 22) =.8031, p = .8031] or days post immunization [F(4, 22) =.579, p = 
.6786], indicating CIA did not induce mechanical allodynia. Although in the plantar stimulator 
test there was also no interaction between treatment and days post immunization [F(4, 22) = 
1.828, p = .1305; Figure 4D] or main effect of days post immunization [F(4, 22) =2.173, p = 
.0786], there was a main effect of treatment [F(1, 22) = 15.612, p <.01], indicating CIA induced 
thermal hyperalgesia. Although there was only a main effect of collagen treatment and not an 
interaction effect in the plantar stimulator test, data for each individual testing day were analyzed 
based on a planned comparison to establish a behavioral timeline. Post hoc analyses revealed 
that CIA induced hyperalgesia on days 22, 31, and 34, but not days 25 or 28 post immunization. 
Based on these data behavioral testing was performed at least 31 days post immunization in all 
proceeding experiments. Although CIA did not induce mechanical allodynia in the preliminary 
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experiment, mechanical allodynia was still tested in experiments one and two, because it 
previously has been the most consistent behavioral test for the CIA model in our lab. 
Experiment 1a: Repeated MAGL inhibitor JZL184 partially attenuates CIA-induced paw 
cytokine level increase 
We next performed repeated administration of the MAGL inhibitor JZL184 (8 or 4 
mg/kg) to establish a subthreshold dose to be combined with the steroid DEX in experiment two. 
Tolerance develops after repeated dosing (6 days) of JZL184 (16 or 40 mg/kg) (Kinsey et al., 
2013; Schlosburg et al., 2010). Therefore, we hypothesized that a lower dose of JZL184 (4 
mg/kg) would be ineffective at attenuating CIA-induced pain and inflammation without causing 
tolerance after repeated administration.  
We first ran mice with only a moderate dose of JZL184 (8 mg/kg) to establish an 
effective dose of JZL184. Acute administration of JZL184 (8 mg/kg) attenuates CIA-induced 
thermal hyperalgesia (Nass, 2015), but these data were obtained before the model was optimized. 
Mice were administered the MAGL inhibitor JZL184 (8 mg/kg, s.c.) or vehicle once daily for 15 
consecutive days starting at the booster. There was an interaction in paw swelling between 
treatment and days post immunization as measured by arthritic clinical scores [F(30, 33) = 
10.544; p <.01; Figure 5A] and paw thickness [F(30, 33) = 7.693; p <.01; Figure 5B]. Post hoc 
comparisons revealed that CIA increased arthritic scores and paw thickness. Furthermore, post 
hoc analyses also indicated a statistical increase in paw swelling in JZL184/CIA mice compared 
to CIA. However, based on data from other cohorts of mice the effect is probably due to 
differences in paw swelling across collagen exposed mice and unlikely to replicate. Thus, the 
JZL184 effect is probably not biologically relevant.   
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Mice were tested for mechanical allodynia and thermal hyperalgesia on day 14 post 
booster. There was a significant effect of drug treatment on mechanical allodynia [F(2, 33) = 
4.653, p <.05; Figure 5C], although post hoc analyses indicated CIA did not induce mechanical 
allodynia. CIA induced thermal hyperalgesia [F(2, 33) = 11.623, p <.01; Figure 5D], but 
JZL184 (8 mg/kg) did not reverse this CIA-induced thermal hyperalgesia.  
Mice were humanely euthanized day 15 post booster and hind limb tissue were harvested. 
Right hind paws were separated and homogenized. A sandwich ELISA was used to analyze 
proinflammatory (TNFα, IL-1β, IL-6, and IL-17) and anti-inflammatory (IL-10) cytokine and 
MPO levels. CIA significantly increased paw levels of the proinflammatory cytokines TNFα [F 
(2, 33) = 7.298, p <.01; Figure 6A], IL-1β [F(2, 33) = 7.149, p <.01; Figure 6B], IL-6 [F(2, 33) 
= 9.188, p <.01; Figure 6C], and IL-17 [F(2, 33) = 7.069, p <.01; Figure 6D], the anti-
inflammatory cytokine IL-10 [F(2, 33) = 8.978, p <.01; Figure 6E], and the neutrophil marker 
MPO [F(2, 33) = 16.859, p <.01; Figure 6F]. Post hoc analyses revealed that the JZL184/CIA 
mice did not significantly differ in proinflammatory (TNFα, IL-1β, IL-6, and IL-17) and anti-
inflammatory (IL-10) cytokine from either the CIA or control mice. These results suggest that 
JZL184 (8 mg/kg) partially attenuates cytokine levels in CIA paws. MPO levels were not 
affected by JZL184 (8 mg/kg).   
Due to the partial attenuation of CIA paw inflammation by JZL184 (8 mg/kg), we next 
tested a separate group of mice with a low dose of JZL184 (4 mg/kg) to establish a subeffective 
dose. For 18 consecutive days, mice were administered the MAGL inhibitor JZL184 (4 mg/kg, 
s.c.) or vehicle once daily. There was an interaction between treatment and days post 
immunization in clinical scores [F(34, 27) = 5.854; p <.01; Figure 7A] and caliper 
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measurements [F(34, 27) = 6.310; p <.01; Figure 7B]. Post hoc comparisons revealed that CIA 
increased paw swelling, but JZL184 (4 mg/kg) was ineffective. 
On day 15 post booster, mice were tested for pain-related behaviors. CIA did not induce 
mechanical allodynia [F(2, 27) = 1.701; p =.2015; Figure 7C] or thermal hyperalgesia [F(2, 27) 
= 1.722; p =.4340; Figure 7D]. Due to the lack of CIA effect, there was no JZL184 (4 mg/kg) 
attenuation of pain-related behaviors. 
On day 18 post booster mice were humanely euthanized and hind limbs were harvested. 
Similar to the previous experiment, CIA significantly increased paw levels of cytokines TNFα [F 
(2, 27) = 7.298, p <.01; Figure 8A], IL-1β [F(2, 27) = 5.662, p <.01; Figure 8B], IL-6 [F(2, 27) 
= 7.378, p <.01; Figure 8C], IL-17 [F(2, 27) = 12.035, p <.01; Figure 8D], IL-10 [F(2, 27) = 
7.547, p <.01; Figure 8E]. However, CIA did not significantly increase MPO [F(2, 27) = 3.294, 
p =0525; Figure 8F] levels. Post hoc analyses revealed that JZL184 (4 mg/kg) had no effect on 
pro and anti-inflammatory (IL-10) cytokine levels or MPO.  
These data reveal that JZL184 (4 mg/kg) is subeffective in CIA-induced paw swelling 
and inflammatory mediators.  
Experiment 1b: Repeated steroid dexamethasone attenuates CIA-induced pain and 
inflammation 
We next performed a dose response curve of repeated administration of the steroid DEX 
to establish a subthreshold dose to be combined with JZL184 in experiment two. Repeated (15 
days) DEX (0.5 mg/kg) administration attenuates CIA-induced paw swelling, allodynia, and 
hyperalgesia (Unpublished data from our lab). Therefore, we hypothesized that repeated 
administration of a lower dose of DEX (0.25 mg/kg or below) would yield a subthreshold dose 
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that does not attenuate arthritic signs. CIA induced paw swelling as measured by clinical scores 
[F(15, 18) = 5.259; p <.01; Figure 9A] and paw thickness [F(15, 18) = 4.527; p <.01; Figure 
9B] compared to non-CIA controls. Mice were administered the steroid DEX (0.0625, 0.125, 
0.25, or 0.5 mg/kg; s.c.) or vehicle once daily for 15 consecutive days. In CIA mice there was an 
interaction between drug treatment and days post immunization in clinical scores [F(4, 60) = 
4.902; p <.01; Figure 9A] and paw thickness [F(4, 60) = 4.388; p <.01; Figure 9B]. Post hoc 
comparisons revealed that all doses of DEX attenuated CIA-induced increase in arthritic scores 
and paw diameter.  
Mice were tested for allodynia and hyperalgesia on day 15 post booster. CIA had no 
effect on mechanical allodynia, compared to control mice [t(18) = 1.828, p = .0842; Figure 9C]. 
However, DEX (0.0625, 0.125, or 0.5 mg/kg) decreased paw withdrawal thresholds in the von 
Frey test [F(4, 43) = 4.537; p < .01; Figure 9C], indicating an anti-allodynic effect. Similarly, 
CIA per se did not induce thermal hyperalgesia in the plantar stimulator test [t(18) = 1.144, p = 
.2674; Figure 9D]. DEX had no effect on thermal hyperalgesia as compared with CIA mice [F 
(4, 43) = .184; p = .9456; Figure 9D]. Due to the robust reduction in paw swelling by DEX (all 
doses), ELISAs were not run to determine cytokine and MPO levels in these mice. 
Because DEX (≥0.0625 mg/kg) attenuated CIA-induced paw swelling, we ran a second 
dose response curve with lower doses of DEX (i.e., 0.015625 or 0.03125 mg/kg) to find a 
subthreshold dose. The highest dose (i.e., 0.5 mg/kg) and negative controls were also included. 
CIA increased arthritic clinical scores [F(14, 18) = 11.310; p <.01; Figure 10A] and paw 
thickness [F(14, 18) = 6.493; p <.01; Figure 10B] compared to non-CIA controls. For 20 
consecutive days mice were administered DEX or vehicle once daily. There was a significant 
interaction between DEX treatment and days post immunization in mice administered collagen in 
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clinical scores [F(42, 32) = 6.493; p <.01; Figure 10A] and paw thickness [F(42, 32) = 5.470; p 
<.01; Figure 10B]. Post hoc analyses revealed all doses of DEX (≥0.015625 mg/kg) attenuated 
CIA-induced hind paw thickness, but clinical scores were reduced at (≥0.03125 mg/kg DEX). 
On day 19 post booster, CIA increased mechanical allodynia [t(18) = 5.916, p <.01; 
Figure 10C] and thermal hyperalgesia [t(18) = 4.829, p <.01; Figure 10D], as compared to non-
CIA control mice. Interestingly, in CIA mice, only the high dose DEX (0.5 mg/kg) attenuated 
mechanical allodynia [F(3, 33) = 4.919; p < .01; Figure 10C] and thermal hyperalgesia [F(3, 32) 
= 3.559, p <.05; Figure 8D].  
Mice were humanely euthanized on day 20 post booster and proinflammatory (TNFα, IL-
1β, IL-6, and IL-17) and anti-inflammatory (IL-10) cytokine and MPO paw levels were analyzed 
by sandwich ELISA. CIA significantly increased paw levels of IL-1β [t(18) = -2.791, p <.05; 
Figure 11B], IL-6 [t(18) = -3.043, p <.01; Figure 11C], and IL-10 [t(18) = -2.605, p <.05; 
Figure 11E] as compared to non-CIA controls. The CIA increase in IL-1β [F(3, 32) = 5.317, p 
<.01; Figure 11B], IL-6 [F(3, 32) = 6.900, p <.01; Figure 11C], and IL-10 [F(3, 32) = 4.573, p 
<.01; Figure 11E] tissue levels was attenuated by all doses of DEX (≥0.015625 mg/kg). 
Similarly, the paw levels of TNFα [t(18) = -2.703, p <.05; Figure 11A], IL-17 [t(18) = -2.112, p 
<.05; Figure 11D], and MPO [t(18) = -4.363, p <.01; Figure 11F] were increased in CIA mice 
compared to non-CIA controls. However, only DEX (≥0.03125 mg/kg) attenuated the CIA 
increase in paw TNFα [F(3, 32) = 4.552, p <.01; Figure 11A], IL-17 [F(3, 32) = 3.724, p <.05; 
Figure 11D], and MPO [F(3, 32) = 6.941, p <.01; Figure 11F].  
These data indicate that DEX (0.015625 mg/kg) was ineffective at attenuating CIA-
induced arthritic clinical scores, pain-related behavior, and proinflammatory cytokines TNFα and 
IL-17 and MPO paw levels. Therefore, DEX (0.015625 mg/kg) was used in Experiment Two.  
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Experiment 2a: Repeated dual administration of the MAGL inhibitor JZL184 and the 
steroid dexamethasone attenuates CIA-induced paw swelling 
In Experiment Two, we determined the effects of dual administration of subeffective 
doses of the MAGL inhibitor JZL184 (4 mg/kg) and the steroid DEX (0.015625 mg/kg), as 
established in Experiment One. We hypothesized that combined JZL184 and DEX would 
attenuate CIA-induced arthritic signs, but would be ineffective alone. CIA increased arthritic 
clinical scores [F(19, 18) = 11.098; p <.01; Figure 12A] and paw thickness [F(19, 18) = 6.348; p 
<.01; Figure 12B] compared to non-CIA controls. Mice were administered the MAGL inhibitor 
JZL184 (4 mg/kg), the steroid DEX (0.015625 mg/kg), a combination of JZL184 (4 mg/kg) and 
DEX (0.015625 mg/kg), or vehicle subcutaneously once daily for 19 consecutive days. In CIA 
mice, there was a significant interaction between treatment and days post immunization in 
clinical scores [F(60, 43) = 4.902; p <.01; Figure 12A] and paw thickness [F(60, 43) = 4.388; p 
<.01; Figure 12B]. Post hoc comparisons revealed that DEX and coadministration of 
JZL184/DEX attenuated CIA-induced arthritic clinical scores and paw thickness.  
Mice were tested for mechanical allodynia and thermal hyperalgesia on day 19 post 
booster. CIA-induced mechanical allodynia [t(18) = 2.210, p <.05; Figure 12C] compared to 
non-CIA control mice. However, in mice administered collagen JZL184, DEX, or JZL/DEX did 
not attenuate the CIA-induced increase in paw withdrawal thresholds in the von Frey test [F(3, 
33) = 1.729; p =.1801; Figure 12C]. CIA did not induce thermal hyperalgesia [t(18) = 1.660, p 
=.1142; Figure 12D]. Due to the lack of a CIA effect, post hoc comparisons revealed no 
significant attenuation of hyperalgesia by JZL184, DEX, or JZL/DEX [F(3, 33) = 1.611, p 
=.2056; Figure 12D]. Taken together, these results suggest that JZL/DEX attenuates CIA-
induced paw swelling, but the effect is probably driven by DEX. 
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Experiment 2b: Repeated dual administration of the MAGL inhibitor JZL184 and the 
steroid dexamethasone did not attenuate CIA-induced increase in paw cytokines and MPO 
Mice were humanely euthanized on day 19 post booster and hind limbs were taken. 
Proinflammatory (TNFα, IL-1β, IL-6, and IL-17) and anti-inflammatory (IL-10) cytokine and 
MPO levels were analyzed by sandwich ELISA. CIA significantly increased paw levels of the 
proinflammatory cytokines TNFα [t(18) = -2.521, p <.05; Figure 13A], IL-1β [t(18) = -2.635, p 
<.05; Figure 13B], IL-6 [t(18) = -32.535, p <.05; Figure 13C], IL-17 [t(18) = -2.416, p <.05; 
Figure 13D], and the neutrophil marker MPO [t(18) = -4.036, p <.01; Figure 13F] as compared 
to non-CIA controls. CIA paw tissue increase in TNFα [F(3, 33) = 1.058, p =.3801; Figure 
13A], IL-1β [F(3, 33) = .569, p =.6392; Figure 13B], IL-6 [F(3, 33) = .856, p =.4733; Figure 
13C], IL-17 [F(3, 33) = .985, p =.4118; Figure 13D], and MPO [F(3, 33) = 1.100, p =.3632; 
Figure 13F] was unaffected by JZL184 (4 mg/kg), DEX (0.015625 mg/kg), or JZL184 (4 
mg/kg) + DEX (0.015625 mg/kg). Similarly, CIA did not increase paw tissue levels of IL-10 
[t(18) = -1.475, p =.1575; Figure 13E] and JZL184, DEX, or JZL/DEX had no effect on IL-10 
[F(3, 33) = 1.1274, p =.2995; Figure 13E].  
Taken together, these data indicate that dual administration of JZL184/DEX did not 
affect the CIA-induced increase in proinflammatory cytokines or MPO paw tissue levels. 
Discussion 
 The overall goal of the present study was to elucidate the effects of targeting cannabinoid 
and glucocorticoid receptors alone and in combination, to attenuate pain and inflammation 
caused by the collagen-induced arthritis (CIA) mouse model of inflammatory arthritis. This is 
the first study to investigate monoacylglycerol lipase (MAGL) inhibition in a chronic pain 
model, either alone or in combination with the synthetic steroid dexamethasone (DEX).  
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 The first aim (Exp 1a) of the present study was to determine the efficacy of the selective 
MAGL inhibitor JZL184 in attenuating inflammatory arthritis. Repeated administration of 
JZL184 (4 or 8 mg/kg, s.c.) did not attenuate CIA-induced paw swelling. However, JZL184 (8 
mg/kg) partially attenuated the CIA-increased proinflammatory (IL-1β, TNFα, IL-6, & IL-17) 
and anti-inflammatory (IL-10) cytokines. These data align with previous studies demonstrating 
that MAGL inhibition by JZL184 attenuates proinflammatory (IL-1β, TNFα, & IL-6) and anti-
inflammatory (IL-10) cytokines in other preclinical models of inflammation (Kerr et al., 2013; 
Kinsey et al., 2011c).  
 The second Aim (Exp 1b) of the present study was to determine the efficacy of the 
synthetic glucocorticoid receptor agonist dexamethasone on CIA-induced inflammation and pain. 
Repeated administration of DEX (≥0.03125 mg/kg, s.c.) attenuated CIA-induced arthritic clinical 
scores. DEX (≥0.015625 mg/kg, s.c.) attenuated the CIA-increased proinflammatory (IL-1β & 
IL-6) and anti-inflammatory (IL-10) cytokines, whereas DEX (≥0.03125 mg/kg, s.c.) attenuated 
the CIA-increased proinflammatory (TNFα and IL-17) cytokines and MPO. These results 
confirm previous reports that DEX attenuates CIA-induced paw swelling and cytokine levels 
(Inglis et al., 2007a; Kawalkowska et al., 2016; Pu et al., 2016). This is the first report to show 
that DEX (0.5 mg/kg, s.c.) also attenuates CIA-induced allodynia and hyperalgesia. 
 The third Aim (Exp 2) of the present study was to determine the behavioral and immune 
effects of dual administration of subeffective doses of both JZL184 and dexamethasone. Due to 
its absence of anti-inflammatory effects in overt paw swelling and paw cytokine levels, the 4 
mg/kg dose of JZL184, was chosen. Similarly, the 0.015625 mg/kg dose of DEX was chosen, 
due to its lack of attenuation of CIA-induced arthritic clinical scores and paw cytokine (IL-1β, 
IL-6, & IL-10) levels. Repeated dual administration of JZL184 (4 mg/kg) and DEX (0.015625 
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mg/kg) attenuated CIA-induced paw swelling. However, solo DEX (0.015625 mg/kg) also 
reduced paw swelling to a similar extent as JZL184/DEX, indicating that this effect is probably 
driven by DEX. JZL184/DEX did not attenuate the CIA-induced increase in pro-inflammatory 
cytokine and MPO paw levels. 
 There is a paucity of research on behavior using the CIA model of inflammatory arthritis. 
Hence, we first performed a behavioral time course and determined that in our lab, CIA-induced 
thermal hyperalgesia starting 31 days post immunization, which corresponds to the beginning of 
a significant increase in paw swelling in CIA mice. These results align with previous reports that 
the onset of CIA-induced thermal hyperalgesia coincides with a significant increase in paw 
swelling in rats (Nieto, Clark, Grist, Chapman, & Malcangio, 2015). It was surprising that 
repeated administration of JZL184 (8 mg/kg) did not attenuate CIA-induced thermal 
hyperalgesia, because MAGL inhibition attenuates acute inflammatory pain induced by 
intraplantar injection of carrageenan (Ghosh et al., 2012; Ignatowska-Jankowska et al., 2013), a 
seaweed extract known to cause paw swelling. One possible explanation for the weak MAGL 
effect is that the inflammatory response in our model is more robust than other models. In 
support of this idea, JZL184 (8 mg/kg) did not reduce overt paw swelling despite partially 
attenuating paw cytokine levels. Alternatively, the mice may have developed partial tolerance to 
repeated JZL184 administration. Repeated administration of high doses (e.g., 40 mg/kg or 16 
mg/kg) of JZL184 reduces CB1 expression and sensitization (Schlosburg et al., 2010). 
Furthermore, tolerance develops to the analgesic and gastroprotective effects of JZL184 after 
repeated administration (6 days) of high doses (40 mg/kg or 16 mg/kg), but not low dose (4 
mg/kg) in mice (Kinsey et al., 2013; Schlosburg et al., 2010). Although the lower dose of 
JZL184 (8 mg/kg) used in the present study did not show tolerance at the cytokine level after 15 
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days of repeated dosing, the effects of a 15 day treatment of JZL184 on cannabinoid receptor 
expression and sensitization are unknown and may reflect differences in CB1 vs. CB2 
susceptibility to tolerance.  
 Tolerance to JZL184 may be prevented at low doses (Kinsey et al., 2013). Therefore, we 
ran a separate cohort of mice to investigate the effects of JZL184 (4 mg/kg) on CIA-induced pain 
and inflammation. JZL184 (4 mg/kg) did not attenuate CIA-induced paw swelling or paw 
cytokine levels, indicating that 4 mg/kg is a subeffective dose in the CIA model. That said, there 
was no CIA effect in either the von Frey or plantar stimulator tests to use as a comparison group 
to properly determine the potential anti-analgesic effects of JZL184 (4 mg/kg). Although the von 
Frey and plantar stimulator tests are the most commonly reported preclinical pain tests in the 
CIA model (Gao et al., 2015; Impellizzeri et al., 2013; Inglis et al., 2007b), in our hands, 
behavior in either test was highly variable across cohorts. Therefore, we also piloted grip 
strength, which may discern CIA-induced loss of muscle function. In the grip strength test, a 
mouse is inverted on a wire cage bottom and the latency to fall from the wire is measured 
(Hutter-Saunders, Gendelman, & Mosley, 2012). We found the paw swelling interferes with the 
ability to grip the wire, as CIA mice showed a significant reduction in latency to fall from the 
wire that was unaffected by JZL184 treatment (please see Appendix A). 
 The overall goal of the present study was to find a subeffective dose of the steroid DEX 
to combine with the MAGL inhibitor JZL184 to reduced CIA-induced pain and inflammation.  
The steroid DEX is a well-known anti-inflammatory drug that attenuates CIA-induces paw 
swelling (Inglis et al., 2007a; Kawalkowska et al., 2016) and proinflammatory cytokines (e.g., 
IL-1β, TNFα, IL-6, & IL-17) in the serum of RA patients and rats subjected to CIA (Colin et al., 
2010; Pu et al., 2016; Schlaghecke et al., 1994). Furthermore, DEX attenuates LPS-induced paw 
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edema and tissue increase of the proinflammatory cytokines IL-1β and TNFα (Naidu, Kinsey, 
Guo, Cravatt, & Lichtman, 2010). Due to its potent anti-inflammatory effects, it was difficult to 
select a subeffective dose of DEX in the present study. After running two dose response curves it 
was determined that DEX (≥0.03125 mg/kg) attenuates CIA-induced paw swelling and increase 
in paw cytokine levels. DEX (0.015625 mg/kg) did not reduce CIA-induced arthritic clinical 
scores, mechanical allodynia, or thermal hyperalgesia and therefore, was chosen as the dose 
coadministered with JZL184.  
 We confirmed data from published reports that high dose DEX attenuates CIA 
inflammation, including paw swelling, clinical scores, and proinflammatory cytokine levels 
(Inglis et al., 2007a; Kawalkowska et al., 2016; Pu et al., 2016). We extended these findings by 
demonstrating that repeated DEX (0.5 mg/kg) administration also attenuates CIA-induced 
mechanical allodynia and thermal hyperalgesia. The observed analgesic and anti-inflammatory 
effects of DEX on inflammatory pain and paw swelling in the chronic CIA model is consistent 
with previous literature that DEX attenuates pain and edema in acute models of inflammatory 
pain (S. H. Ferreira et al., 1997; Naidu et al., 2010; Sasso et al., 2012). The present data, together 
with previous studies, suggest that DEX attenuates both chronic and acute inflammatory pain and 
inflammation. However, from a practical point of view, steroid hormones are not a viable long-
term treatment for RA, especially at high doses, due to their harmful side effects such as 
metabolic problems, adrenal insufficiency, osteoporosis, and mood changes (Nelson, 2011).  
 Therefore, the third goal of the present study was to coadminister subeffective doses of 
the MAGL inhibitor JZL184 and the steroid DEX to attenuated CIA-induced arthritic signs while 
mitigating aversive side effects. The combination of low doses of JZL184 and DEX attenuated 
arthritic clinical scores in the present study, but the combination group did not differ from the 
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DEX treated group, which indicates that the observed anti-inflammatory effect was likely driven 
by DEX and not JZL184. Although two dose response curves of DEX were run in present study, 
it is plausible that an even lower dose of DEX than we selected would yield a clearer 
coadministration effect. Indeed, despite the lack of a reduction in arthritic clinical scores by DEX 
(0.015625 mg/kg) in the dose response curve in Exp 1b, this same DEX dose did attenuate paw 
swelling in Exp 2. In support of the idea that DEX drove the anti-inflammatory effects, other labs 
have reported that glucocorticoids dominate the attenuation of CIA-induced paw swelling in 
combined treatments (Joosten et al., 1999; Kang, Lee, & Lee, 2000; Kawalkowska et al., 2016).  
For example, dual administration of DEX (0.25 or 0.025 mg/kg) and the anti-inflammatory 
cytokine IL-4 reduced paw inflammation, whereas IL-4 alone was ineffective, suggesting that the 
anti-inflammation was predominantly driven by DEX (Kang et al., 2000; Kawalkowska et al., 
2016). When DEX is repeatedly administered and then administration in halted, mice subjected 
to CIA demonstrate a “rebound” effect with exaggerated paw swelling once DEX is withheld 
(Kang et al., 2000; Kawalkowska et al., 2016). Interestingly, mice administered the dual 
DEX/IL-4 treatment had less of a rebound of paw swelling than mice in the DEX-only treatment 
(Kawalkowska et al., 2016). These data indicate that, although DEX may dominate the anti-
inflammatory effects of combined treatment, it is plausible that dual administration with another 
anti-inflammatory mediator may continue to reduce inflammation after DEX treatment is 
terminated. Steroid discontinuation-induced inflammation is problematic for patients of chronic 
inflammatory disorders because steroids are recommended only for short-term use due to their 
aversive side effects (Singh et al., 2016). Unfortunately, in the present study the protection of 
JZL184 against DEX discontinuation-induced inflammation was not tested because paw tissue 
was harvested to determine for cytokines, but the idea of MAGL inhibition protecting from 
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“steroid rebound” warrants further investigation. For example, mice may be subjected to CIA 
and administered DEX (as in Exp 1b) with or without JZL184. When DEX administration is 
suspended, a rebound effect (e.g., paw swelling) would be expected in DEX-treated mice, but 
JZL184 may attenuate such paw swelling. 
 Only one dose of JZL184/DEX coadministration was tested in the present study due to 
time and expense constraints, but it would be worth exploring multiple doses of JZL184/DEX for 
dual administration. The goal of the present study was to combine subeffective doses of both 
drugs to attenuate CIA-induced pain and inflammation to the same degree as an effective dose of 
either drug alone. Nevertheless, coadministration of subeffective doses of JZL184/DEX only 
reduced arthritic clinical scores. Although solo DEX attenuated CIA-induced inflammation and 
pain at high doses, aversive side effects limit the use of steroids in a clinical setting (Ravindran et 
al., 2009).  However, solo JZL184 partially attenuated CIA-induced increase in paw cytokine 
levels at the 8, but not 4 mg/kg dose. Therefore, subeffective DEX combined with a partially 
effective dose of JZL184 (i.e., 8 mg/kg) may yield a greater anti-arthritic effect compared to only 
a subeffective dose of JZL184, while limiting the risks associated with steroid use.  
 Although dual administration of JZL184 and DEX did not attenuate the CIA-induced 
increase in paw pro- and anti-inflammatory cytokine levels, the combination treatment partially 
attenuated MPO, a marker of neutrophil activation. This blunted MPO response may indicate 
that JZL184/DEX attenuates paw swelling by reducing immune cell activation, rather than by 
decreasing immune cell signaling. To better address this hypothesis, it would be interesting to 
quantify paw levels of different types of immune cell using flow cytometry. Dual administration 
of DEX/IL-4 decreases the amount of pro-inflammatory Th-17 cells, while increasing the 
amount of anti-inflammatory Treg cells (Kawalkowska et al., 2016). Thus, in addition to 
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decreasing neutrophil activity, the combination of JZL184/DEX may also attenuate the activity 
of other immune cells involved in RA, including macrophages, T cells, and B cells.  
 Due to the decrease in CIA-induced paw swelling by coadministration of JZL184/DEX 
future studies may also investigate joint tissue damage, using histology. Previous reports indicate 
that FAAH inhibition or CB2 receptor agonism attenuates paw swelling and joint degradation 
(Fukuda et al., 2014; Gui et al., 2015; Kinsey et al., 2011b). These data, along with the present 
study, suggest that dual administration of JZL184/DEX may also reduce CIA-induced joint 
damage. 
 A potential limitation of this study is that the dosing schedule was prophylactic and mice 
received drug treatment prior to the development of paw swelling. Prophylactic treatments are 
important for a variety of medical conditions that have an increased likelihood of occurring, 
including thromboembolic disease or infection after surgeries (Alhassan et al., 2017; Enzler, 
Berbari, & Osmon, 2011). Further, vaccines are a major source of preventative treatments 
(Rappuoli, Pizza, Del Giudice, & De Gregorio, 2014). However, most disorders are not 
detectable until the symptoms are present, and therefore must be treated therapeutically. In 
preclinical research both types of designs offer distinct advantages. Therapeutic dosing regiments 
are crucial in preclinical models to increase translatability to many human medical disorders. 
However, investigating preventative treatment is also useful in preclinical research. Although 
translatability is essential, it also is important to know if an effect is worth pursing further. In the 
present study there was a lack of an anti-inflammatory or analgesic effect after preventative 
treatment with the combination of JZL184 and DEX. Given that JZL/DEX could not prevent 
paw inflammation from developing, it is unlikely that dual administration would be anti-
inflammatory after paw inflammation was already present. 
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 A significant limitation of the CIA model chosen for the present study is that there was 
insufficient CIA induction of allodynia or hyperalgesia to determine the potential analgesic 
effects of dual JZL184/DEX treatment. In addition to the behavioral tests used, another potential 
reason for the inconsistent pain behavior is the CIA model itself. Although CIA is a great model 
of inflammatory arthritis, due to the strong similarities in pathogenesis with RA, there are many 
complicating factors in this model that make it difficult to use. For example, the presence of paw 
swelling is an obvious indication of collagen exposure. In the present study this was mitigated by 
blinding the experimenter to drug treatment, but due to the nature of the behavioral assays and 
paw swelling measurements it is impossible to blind an experimenter to the presence of paw 
swelling. Another limitation is that some of the mice immunized to collagen never develop paw 
swelling (Brand et al., 2007). The incidence of paw swelling in non-drug treated mice in our lab 
is typically above 80%, but there is considerable variance between experiments, a reflection of 
the variance of CIA responses between mouse cohorts. Furthermore, swelling across paws is not 
uniform in each individual mouse and paw swelling across mice is inconsistent. Multiple 
methodological refinements were made to increase consistency across cohorts. We also tried to 
mitigate inconsistencies across cohorts of mice by having only one rater across all experiments to 
increases internal reliability. Although interrater reliabilities were conducted periodically to 
minimize drift, having only one rater may decrease reproducibility. A possible remedy to the 
problem of variance in swelling across paws and incidence across cohorts is to trade the strong 
mechanistic link between RA and CIA for more control within each experiment by using a 
different model of inflammatory arthritis.  
 In contrast to the CIA model, which is mainly used to research RA immunosuppressant 
treatments, injection of an inflammatory mediator into the footpad is extensively used to 
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characterize chronic inflammatory pain (Ghasemlou, Chiu, Julien, & Woolf, 2015; Inglis et al., 
2007b). For example, intraplantar injection of CFA (without collagen, as is used in the CIA 
model) into the hind paw footpad of rodents induces chronic inflammatory pain in the injected 
paw, but not contralateral paw (Bagdas, AlSharari, Freitas, Tracy, & Damaj, 2015). Although 
intraplantar injection of an inflammatory agent induces fairly consistent edema and swelling 
across animals, the immune response does not activate lymphocytes of the adaptive immune 
system, and thus does not model the autoimmune response germane to rheumatoid arthritis RA 
(Ghasemlou et al., 2015). This disconnect between inflammatory research and pain research 
limits external validity and translational potential. For example, many immunosuppressant 
treatments for RA are ineffective at attenuating pain (Lee, 2013). Data from our lab indicate that 
the CB2 receptor agonist HU-308 attenuates CIA-induces paw swelling, but has no effect on 
allodynia; whereas HU-308 attenuates CFA-induced hyperalgesia, but not paw edema (see 
Appendix B). These data indicate the importance of incorporating behavioral tests into 
traditional models of inflammatory arthritis to develop novel treatments for RA that reduce both 
pain and inflammation. 
 Another alternative to the CIA model that is gaining popularity among inflammatory 
arthritis researchers is the collagen-antibody-induced arthritis (CAIA) model. In the classic CIA 
model, antibodies to self-collagen are produced by the mice. In the CAIA model, arthritis is 
induced by administration of these anti-collagen antibodies, along with immune stimulation by 
the gram-negative bacterial marker lipopolysaccharide (Kagari, Doi, & Shimozato, 2002). 
Swelling develops in one or more paws within 10 days and lasts approximately three weeks. 
Inflammation eventually leads to cartilage and bone destruction, similar to CIA and RA. The 
major benefit of CAIA is that the time course is more rapid than in CIA, but unlike RA and CIA 
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the joint inflammation in the CAIA model is not perpetuated by the T-cells of the adaptive 
immune system that are important in the induction of autoimmune disorders (Asquith et al., 
2009; Kagari et al., 2002). We conducted a pilot study using the CAIA model (see Appendix C), 
but unfortunately the CAIA mice did not develop significant paw swelling compared to non-
CAIA control mice, and thus MAGL inhibition was not anti-inflammatory. We consulted with 
the vendor, who was unable to explain the lack of arthritic development. Regardless, CAIA is 
reported to induce arthritis in multiple mouse strains that are resistant to CIA, as well as females 
(Khachigian, 2006). Thus, CAIA may offer broader opportunities to investigate cannabinoid 
effects on inflammatory arthritis, for example using genetic knockout mice that do not express 
MAGL.  
 In summary, we found that MAGL inhibition partially reduces paw inflammation caused 
by collagen-induced arthritis. This is the first demonstration of an anti-inflammatory effect of 
MAGL inhibition and an analgesic effect of DEX in a chronic inflammatory joint pain model. As 
previously demonstrated, the synthetic glucocorticoid dexamethasone was a potent anti-
inflammatory agent. Overall, the effects of either drug varied by test, by model, and by cohort. 
This variance may explain why behavioral data are rarely reported in the preclinical 
inflammatory arthritis literature. Given the strong negative side effects of current arthritis 
treatments, including but not limited to repeated steroid administration, the evidence that MAGL 
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Figure 4. Collagen-induced arthritis (CIA) induces paw swelling and thermal hyperalgesia. Mice 
were administered an emulsion of collagen/CFA and then given a booster exposure to collagen 
21 days later. Control mice were administered an emulsion of acetic acid/IFA. CIA mice 
developed an increase in arthritic clinical scores (A) and hind paw thickness (B). Mice were 
tested for pain-related behaviors on days 22, 25, 28, 31, and 34 post immunization. Mice did not 
develop mechanical allodynia tested via the von Frey assay (C), but did develop thermal 
hyperalgesia in the plantar stimulator test (D). Data expressed as mean ± SEM (n = 12).  # p < 
0.05 vs. control mice. 




Figure 5. Repeated dosing of the MAGL inhibitor JZL184 (8 mg/kg) did not affect paw 
swelling, allodynia, or hyperalgesia in mice subjected to CIA. Mice were administered JZL184 
(8 mg/kg, s.c.) or vehicle for 15 days. JZL184 did not attenuate CIA-induce paw swelling as 
measured by clinical scores (A) or paw thickness (B). CIA mice did not develop mechanical 
allodynia (C), but did develop thermal hyperalgesia (D). Data expressed as mean ± SEM (n = 
12). * p < 0.05 vs. CIA mice; # p < 0.05 vs. control mice. 
  




Figure 6. Repeated dosing of the MAGL inhibitor JZL184 (8 mg/kg) partially attenuated CIA-
induced increase in paw levels of proinflammatory (TNFα, IL-1β, IL-6, and IL-17) (A-D) and 
anti-inflammatory (IL-10) (E) cytokines. JZL184 did not affect the CIA-induced increase in 
MPO (F), a marker of neutrophil activity. Mice were administered JZL184 or vehicle for 15 
days. Data expressed as mean ± SEM (n = 12). # p < 0.05 vs. control mice. 
  




Figure 7. Repeated dosing of the MAGL inhibitor JZL184 (4 mg/kg) was subeffective at 
attenuating CIA-induced paw swelling. Mice were administered JZL184 or vehicle for 18 days. 
JZL184 did not attenuate the CIA-induce increase in arthritic clinical scores (A) or hind paw 
thickness (B). CIA mice did not develop mechanical allodynia (C) or thermal hyperalgesia (D). 
Data expressed as mean ± SEM (n = 10). # p < 0.05 vs. control mice. 
  




Figure 8. Repeated dosing of the MAGL inhibitor JZL184 (4 mg/kg) was subeffective at 
attenuating the CIA-induced increase in paw levels of proinflammatory (A-D) and anti-
inflammatory (E) cytokines. CIA did not increase paw MPO (F) levels. Mice were administered 
JZL184 or vehicle for 18 days. Data expressed as mean ± SEM (n = 10). # p < 0.05 vs. control 
mice. 
  




Figure 9. Repeated dosing of the steroid dexamethasone (DEX) attenuated paw swelling and 
allodynia, in mice subjected to CIA. Mice were administered DEX or vehicle once daily for 15 
consecutive days. DEX attenuated CIA-induced clinical scores (A) or paw thickness (B). 
Although CIA did not induce mechanical allodynia, DEX attenuated mechanical allodynia (C). 
CIA did not induce thermal hyperalgesia in the plantar test (D). Data expressed as mean ± SEM 
(n = 9-10). * p < 0.05 vs. CIA mice; # p < 0.05 vs. control mice. 
  




Figure 10. Repeated dosing of the steroid dexamethasone (DEX; 0.015625 mg/kg) was 
subeffective at attenuating arthritic clinical scores and pain-related behavior in CIA mice. Mice 
were administered DEX or vehicle once daily for 20 days. DEX attenuated CIA-induced arthritic 
clinical scores (A) paw thickness (B), mechanical allodynia (C), and thermal hyperalgesia (D). 
Data expressed as mean ± SEM (n = 9-10). * p < 0.05 vs. CIA mice; # p < 0.05 vs. control mice. 
  




Figure 11. Repeated dosing of the steroid dexamethasone (DEX) was subeffective at attenuating 
the CIA-induced increase in proinflammatory cytokine (TNFα and IL-17) and MPO paw levels. 
Mice were administered DEX or vehicle once daily for 20 days. DEX attenuated the CIA-
induced paw increase in proinflammatory cytokines (A-D) and the neutrophil marker MPO (F). 
Data expressed as mean ± SEM (n = 9-10). * p < 0.05 vs. vehicle CIA mice; # p < 0.05 vs. 
control mice. 
  




Figure 12. Repeated, dual administration of JZL184/DEX, or DEX alone, attenuated CIA-
induced paw swelling. Mice were administered the JZL184 (4 mg/kg; s.c.), DEX (0.015625 
mg/kg; s.c.), both JZL184 (4 mg/kg; s.c.) and DEX (0.015625 mg/kg; s.c.), or vehicle once daily 
for 19 days. DEX or JZL184/DEX attenuated CIA-induce arthritic clinical scores (A) and caliper 
measurements (B). CIA-induced mechanical allodynia (C) was not attenuated by drug treatment. 
There was no CIA-induced thermal hyperalgesia (D). Data expressed as mean ± SEM (n = 9-11). 
* p < 0.05 vs. CIA mice; # p < 0.05 vs. control mice. 
 




Figure 13. Repeated dual administration of JZL184/DEX did not affect CIA-induced increase in 
paw levels of proinflammatory cytokine (A-D) and MPO (F). Mice were administered the 
JZL184 (4 mg/kg; s.c.), DEX (0.015625 mg/kg; s.c.), a combination of JZL184 (4 mg/kg; s.c.) + 
DEX (0.015625 mg/kg; s.c.), or vehicle once daily for 19 days. CIA did not affect IL-10 levels 
(E). Data expressed as mean ± SEM (n = 9-11). * p < 0.05 vs. CIA mice; # p < 0.05 vs. control 
mice. 
  




Grip strength as a measure of CIA-induced loss of paw function 
Background 
 As proposed, the present study focused primarily on pain-induced behaviors such as 
mechanical allodynia (increased sensitivity to touch) or thermal hyperalgesia (increased 
sensitivity to noxious heat). These assays were chosen because they are among the most 
commonly used behavioral tests for pain induced by arthritis in rodents (Gao et al., 2015; Inglis 
et al., 2007b). That said, the vast majority of arthritis related reports focus exclusively on 
inflammation and not its resulting pain.  
 In addition, pain-induced behaviors are potentially problematic in that they are easily 
confounded by sedation. For example, mechanical allodynia is reversed by high dose opioids 
(Nagakura et al., 2003), which effectively sedate the test subject. On the other hand, pain-
suppressed behaviors are reversed when the animal increases its behavior, and are thus less 
susceptible to sedative confounds. Thus, the goal of this experiment was to examine a pain-
suppressed behavior as well as a test of functional ability, grip strength. 
Methods 
Thirty male DBA1/J mice were subjected to CIA or control, as described in the main body of the 
document. Half of the CIA mice were repeatedly administered JZL184 (4 mg/kg, s.c.) or vehicle 
for 16 days. The inverted cage lid test (Brooks, Higgs, Jones, & Dunnett, 2012) was used to 
measure grip strength. Mice were placed on the top of a wire cage bottom and the wire was 
briefly shaken to cause the mice to grip the wire. The wire was gently flipped upside-down along 
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the mouse’s y-axis (i.e., pitch, with the mouse’s head going forward and down) and suspended 
approximately 20 cm above a cage filled with soft bedding. The latency for the mouse to drop 
from the wire was measured by a second experimenter using a stopwatch.  
Results 
CIA treatment significantly decreased latency to fall [F(2, 27) = 6.395; p <.01; Figure A1]. Post 
hoc comparisons revealed that repeated JZL184 (4 mg/kg) treatment had no effect on grip 
strength. 
Discussion 
 The inverted cage lid test, a test of grip strength, was surprisingly effective at detecting 
CIA-induced loss of paw function. This low-tech alternative to allodynia and hyperalgesia tests 
has not been reported with CIA in mice, and offers some advantages over established pain 
models. The results align with a previous report indicating that CIA in rats attenuates grip 
strength as measured by the force used to grip a wire grid to resist the tail being pulled by a 
spring balance (Sasakawa, Sasakawa, Ohkubo, & Mutoh, 2005). One advantage of the method 
used in the present study is that the test requires no special equipment and training is minimal. 
 Watching the mice cling to the wire lid, the differences between CIA and control mice 
was striking. Mice that had significant paw swelling, especially in the forepaws, had the shortest 
latencies to fall from the wire. Mice with overt swelling in both forepaws fell from the lid almost 
immediately. Conversely, mice without paw swelling were able to ambulate along the underside 
of the lid until they reached the maximum cutoff time of one minute.  
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 The idea to assess grip strength came about at the end of the present project, and so there 
was inadequate time to incorporate the test more broadly. So, this brief study was limited to only 
one test point in one cohort of CIA mice. Although MAGL inhibition had no effect on grip 
strength on day 16, time course data may reveal a delay in functional loss. It may be informative 
to measure grip strength repeatedly over the course of CIA development, as a measure of 
functional loss of paw strength.   




Figure A1. Collagen-induced arthritis (CIA) decreases grip strength. Mice were subjected to 
CIA. Mice were administered JZL184 (4 mg/kg, s.c.) or vehicle for 16 days, then grip strength 
was tested using the inverted cage lid test. Data expressed as mean ± SEM (n = 10).  # p < 0.05 
vs. non-CIA control mice. 
  




Anti-arthritic effects of CB2 agonism in CIA and CFA-induced arthritis models 
Background 
 The goals of the present study were (1) to evaluate the possible analgesic effects of the 
CB2 agonist HU-308 in collagen-induced arthritis (CIA) mouse model and (2) to compare the 
anti-inflammatory and analgesic effects of CB2 agonism by HU-308 in the CIA model of 
inflammatory arthritis and the complete Freund's adjuvant (CFA) model of inflammatory pain. 
There are a variety of selective CB2 agonists that have been synthesized to have a greater binding 
affinity for the CB2 receptor over the CB1 receptor. CB2 agonists provide an opportunity to 
harness the anti-inflammatory and analgesic effects of exogenous cannabinoids without the 
undesirable cognitive and behavioral side effects exhibited by more traditional cannabinoid 
agonists, such as THC (Hanus et al., 1999; LaBuda, Koblish, & Little, 2005).  Acute 
administration of CB2 agonists reduces pain and inflammation in several animal models of acute 
inflammatory pain, including intraplantar injection of CFA (Clayton, Marshall, Bountra, & 
O'Shaughnessy, 2002; Kinsey et al., 2011a; Valenzano et al., 2005). However, despite the ability 
of CFA to induced chronic inflammatory pain that can last for weeks, the analgesic effects of 
CB2 agonism have not been evaluated beyond 48 h of inflammatory pain. Further, repeated 
administration of CB2 agonists reduces the inflammation and joint destruction caused by 
collagen induced arthritis (CIA) (Fukuda et al., 2014; Gui et al., 2015), but the analgesic effects 
are unknown.  The present study tested the hypothesis that the CB2 selective agonist HU-308 
decreases inflammation and pain caused by CIA or CFA.  
 




 For the CIA model, male DBA1/J mice were immunized with an emulsion of collagen 
and CFA followed 21 days later by a secondary "booster" exposure to the collagen emulsion, to 
induce anti-collagen autoimmunity. On day 28 mice were administered 25 µg lipopolysaccharide 
(LPS) in 0.1 ml saline (ip) to “synchronize” arthritis induction (Caccese, Zimmerman, & 
Carlson, 1992; Luo et al., 2011). CIA significantly increased paw swelling (i.e. arthritic clinical 
scores [F(32, 27) = 8.794; p <.01; Figure A2A] and caliper measurements [F(32, 27) = 4.136; p 
<.01; Figure A2B]) and mechanical allodynia, per the von Frey test [F(2, 27) = 12.728; p <.01; 
Figure A2C]. Repeated administration of the selective CB2 agonist HU-308 (3 mg/kg, i.p.) for 
10 days significantly attenuated CIA-induced paw swelling. Surprisingly, HU-308 did not affect 
CIA-induced mechanical allodynia.  
CFA-induced arthritis 
 The CIA model is extensively used to research immunosuppressant treatments that 
reduce inflammation and disease progression in inflammatory arthritis. In contrast, intraplantar 
injection of inflammatory mediators is extensively used to characterize novel analgesic 
treatments for chronic inflammatory pain. To test this hypothesis, either complete Freund’s 
adjuvant (CFA, 20 µl) or saline was injected directly into each hindpaw of male C57BL/6 mice 
to induce localized paw inflammation and pain. CFA significantly increased inflammatory pain 
and edema 24h after administration [F(6, 21) = 5.543; p <.01; Figure A2D]. Subchronic 
administration of HU-308 (50 mg/kg, i.p.) attenuated CFA-induced hyperalgesia, per the 
Hargreaves plantar stimulator test [F(2, 21) = 7.464; p <.01; Figure A2E]. In contrast to the CIA 
model, HU-308 did not significantly affect CFA-induced paw edema. 




 Taken together these results suggest a disconnect between the CIA model of 
inflammatory arthritis traditionally used to develop immunosuppresants and the CFA model of 
inflammatory pain used to develop novel analgesic treatments. The CFA model is an attractive 
alternative to the CIA model because of its relatively fast throughput. However, neither model 
reflects all aspects of inflammatory arthritis in humans, and the effects of the synthetic CB2 
agonist HU-308 varied greatly between models. Although the present study provides new 
evidence that CB2 is a potential target for the development of new analgesic anti-inflammatory 
treatments for inflammatory arthritis these results may have reduced external validity and 
translatability. 
  




Figure A2. Disconnect between anti-inflammatory and analgesic effects of the CB2 agonist HU-
308 in the CIA model of inflammatory arthritis and the CFA model of inflammatory pain. To test 
the effects of HU-308 in a model of inflammatory arthritis mice were subjected to CIA and 
administered HU-308 (3 mg/kg, i.p.) for 10 days. HU-308 attenuated CIA-induce paw swelling 
as measured by clinical scores (A) or paw thickness (B). HU-308 did not affect CIA-induced 
mechanical allodynia (C). A separate group of mice was injected in the hind paw with CFA and 
administered HU-308 (50 mg/kg, i.p.) for 4 days. HU-308 reduced CFA-induced edema, but did 
not attenuate CFA-induced hyperalgesia (D). Data expressed as mean ± SEM (n = 8-10). * p < 
0.05 vs. CIA; $ p < 0.05 vs. CFA; # p < 0.05 vs. control mice. Dotted line represented control 
saline paw latencies. 
  




Collagen Antibody-induced Arthritis model 
 
Background 
 The goal of the present study was to pilot the collagen antibody induced arthritis (CAIA) 
model of inflammatory arthritis in the lab. The production of antibodies against self-peptides 
(e.g., rheumatoid factor, anti–citrullinated protein, and collagen) by B cells of the adaptive 
immune system are important in the pathogenesis of both RA and CIA (Asquith et al., 2009; 
Takemura et al., 2001). In the CAIA model, anti-collagen antibodies generated from mice are 
passively transferred to test mice to induce paw swelling and pain (Frolov, Yang, Dong, 
Hammock, & Crofford, 2013; Terato et al., 1992).  
 The CAIA model of inflammatory arthritis has several advantages and disadvantages 
over the more classical CIA model. For example, CAIA develops much faster than CIA (e.g., 
arthritis develops in one or more paws in two weeks, as opposed to five weeks with CIA). 
Further, unlike CIA, which can only be induced in susceptible mice with certain haplotypes of 
the major histocompatibility complex (MHC) class II genes, CAIA can be induced in a wide 
variety of mice strains (Asquith et al., 2009). This flexibility allows researchers to study 
inflammatory arthritis using genetic tools, such as gene knockout and transgenic mice that are 
typically backcrossed on the non-CIA susceptible C57BL/6 mouse strain.  
 On the other hand, although the CAIA model has a quicker throughput compared to CIA, 
arthritis induction is exceedingly more expensive in the CAIA model and the shorter timeline 
might not translate as well to human chronic inflammatory arthritis (Khachigian, 2006). In 
addition, CAIA inflammation is mainly perpetuated by the innate immune response and lacks the 
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critical adaptive T cell immune response needed to perpetuate CIA and RA (Asquith et al., 2009; 
Kagari et al., 2002). The present study tested the hypothesis that CAIA would induce paw 
swelling and pain-related behaviors that would be attenuated by the MAGL inhibitor JZL184 (4 
mg/kg).  
Methods 
Male BALB/c mice were administered a cocktail of anti-collagen antibodies or saline via tail 
vein injection, per manufacturer's protocol (Chondrex, Redmond, WA). Three days later, mice 
were administered lipopolysaccharide (LPS, 50 μg, i.p.) to stimulate the immune response. Mice 
were administered JZL184 (4 mg/kg, s.c.) or vehicle (1:1:18 parts ethanol, cremophor, and 
normal saline) once daily for 15 days. Mice were assessed daily for arthritis, including clinical 
scoring and paw thickness. On the 15th day after immunization, mice were tested for mechanical 
allodynia and thermal hyperalgesia, as detailed in the main body of the dissertation.   
Results 
CAIA did not significantly affect paw swelling (i.e., arthritic clinical scores [F(2, 24) = 2.161; p 
=.1371; Figure A3A] and caliper measurements [F(2, 24) = 1.411; p =.2634; Figure A3B]) or 
thermal hyperalgesia [F(2, 24) = .482; p = .6233; Figure A3D]. However, CAIA did induce 
mechanical allodynia, per the von Frey test [F(2, 24) = 4.654; p < .05; Figure A3C]. Repeated 
JZL184 had no effect on paw swelling or pain-related behaviors.  
Discussion 
 These results suggest that although the CAIA model is broadly reported to be easier to 
induce than the CIA model of inflammatory arthritis, the CAIA model, like CIA, still has 
optimization problems. Although consultation with the vendor did not yield any obvious 
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problems with our induction methodology, it is likely we had slight issues not written in 
published protocols that led to a lower incidence. It is suggested that delivering the antibodies via 
tail vein injection, versus intraperitoneal injection, produces optimal CAIA incidence 
(Khachigian, 2006). Thus, it is possible that some mice accidently received a subcutaneous tail 
injection, which is the least effective method of delivering CAIA. This is unlikely, given that I 
was thoroughly trained by the Office of Laboratory Animal Resources to inject into the tail vein, 
a procedure that I practiced extensively prior to injecting collagen antibodies. Moreover, I 
observed the injection sites for tell-tale blisters that form when injecting subcutaneously or 
intradermally, and observed neither phenomenon. Nevertheless, my opinion is that, with 
optimization, CAIA is a promising model to develop novel treatments for inflammatory arthritis. 
  




Figure A3. CAIA induced mechanical allodynia, but not paw swelling. Mice were administered 
an anti-collagen antibody cocktail to induce CAIA or saline via tail vein injection. Three days 
later mice were administer 50 μg of LPS. Mice were JZL184 (4 mg/kg; s.c.) or vehicle once 
daily for 15 days. CAIA did not induce paw swelling compared to non-CAIA controls as 
measured by clinical scores (A) and calipers (B). CAIA induced mechanical allodynia in the von 
Frey assay (C), but not thermal hyperalgesia in the plantar test (D). JZL184 (4 mg/kg) did not 
affect paw swelling, allodynia, or hyperalgesia. Data expressed as mean ± SEM (n = 9). # p < 
0.05 vs. control mice. 
 
